Home | Business News | Browse by Publication | M | M2 Presswire

Daily Market Movers Digest Midday Stock Alerts, Wednesday, May 31st, ASCE, RHWC, LTII, SCLL, SEVI, WITM.

Article Excerpt
M2 PRESSWIRE-31 May 2006-OTCPicks.com: Daily Market Movers Digest Midday Stock Alerts, Wednesday, May 31st, ASCE, RHWC, LTII, SCLL, SEVI, WITM(C)1994-2006 M2 COMMUNICATIONS LTD

RDATE:31052006

Today our stock watch alerts today include Featured Profiles for Ascentia Biomedical Corporation (OTC: ASCE), Reliant Home Warranty Corp. (OTCBB: RHWC) and stock alerts for Luna Technologies International, Inc. (OTCBB: LTII), Stem Cell Innovations, Inc. (OTCBB: SCLL), Systems Evolution, Inc. (OTCBB: SEVI), Wits Basin Precious Minerals Inc. (OTCBB:WITM)

FEATURED STOCK PROFILE

ASCENTIA BIOMEDICAL CORPORATION (OTC: ASCE)

Detailed Quote: http://www.otcpicks.com/quotes/ASCE.php

View Company Profile: http://www.otcpicks.com/profiles/asce/index.php

Ascentia Biomedical Corporation (OTC: ASCE) is a bio-medical arbitrage and development company. Ascentia purchases profitable dedicated clinical research organizations [CRO] and integrates them into a national branded research organization. The CROs provide the capacity and resources to opportunistically develop Ascentia's pharmaceutical products through Ascentia Biomedical Technologies, Inc.

Ascentia is developing and commercializing new pharmaceutical and biomedical products for application in a number of areas, including treatment for diseases of inflammation [asthma, arthritis] and cancer. Initially, a majority of these products will be secured through direct purchase or licensing. As the Company grows and evolves, more products will be developed internally.

ASCE News:

May 30 - Ascentia Biomedical Announces a Shift to Biomedical Arbitrage and Development to Achieve Profitability

Ascentia Biomedical Corporation (OTC: ASCE), a leading researcher and developer of efficacious pharmaceuticals, compounds and other products, announces that as a part of its new business model, Ascentia will purchase profitable dedicated clinical research organizations [CRO] and integrate them into a national branded research organization. The CRO will provide the capacity and resources to develop Ascentia's preclinical contract research through Ascentia Biomedical Technologies, Inc.

CROs provide independent product development services primarily for the pharmaceutical, biotechnology and medical device industries. Companies in these industries outsource product development services to CROs in order to manage the product development process more efficiently and cost-effectively, and to maximize the benefits in time and profit of patient-protected products.

The company has a letter of intent to purchase its first profitable CRO located in the Southeastern U.S. Additional acquisition candidates have been identified and early discussions are in progress with company representatives. A successful conclusion to the first two acquisitions would provide Ascentia with annual profits of $5 MM. Ascentia working in concert with its investment banker and an international brokerage firm is finalizing the financial terms of the acquisitions.

Dr. James Clagett, President & CEO of Ascentia Biomedical said, "Ascentia's drive for profitability enhances the short and long term goals of Ascentia. It provides access to additional investment capital in the future; resources to continue pharmaceutical development of its two key compounds for treatment of inflammatory diseases; and participation in more senior markets."

FEATURED STOCK PROFILE

RELIANT HOME WARRANTY CORP. (OTCBB: RHWC)

Detailed Quote: http://www.otcpicks.com/quotes/RHWC.php

View Company Profile: http://www.otcpicks.com/profiles/rhwc/index.php

Reliant Home Warranty Corp. (OTCBB: RHWC) operates as a mortgage banking company in Canada/USA. Reliant originates financing, securitizes, services and sells non-prime mortgage loan pools secured by residential real...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!